10 min read
Preclinical Translation Across 19 LATAM Countries
What LATAM regulators and ethics committees actually require translated for the preclinical annex of clinical trial filings — 19 countries, 5 exceptions named.
By Julio G. Martinez-Clark
Field notes
Regulator-specific notes on translation requirements, review workflows, and submission readiness across Latin America.
Filter by topic
9 posts matching your filters
10 min read
What LATAM regulators and ethics committees actually require translated for the preclinical annex of clinical trial filings — 19 countries, 5 exceptions named.
By Julio G. Martinez-Clark
13 min read
The Spanish-specific readability index LATAM IRBs increasingly enforce — and why 98.3% of Spanish ICFs already fail it.
By Julio G. Martinez-Clark
16 min read
Six real translation-grounds RFIs from INVIMA, ANVISA, COFEPRIS, ANMAT, ISP and DIGEMID: the flagged clause, the error, and the delay each caused.
By Julio G. Martinez-Clark
11 min read
A document-by-document, country-by-country read on when LATAM and global regulators require a sworn public translator, when a certified statement is enough, and when neither is required at all.
By Julio G. Martinez-Clark
12 min read
A module-level map of submission-language rules for devices, pharmaceuticals, and biologics across LATAM and the major global authorities — including where English is accepted and where it never is.
By Julio G. Martinez-Clark
12 min read
How to build a translation quality process a regulator can audit — fidelity checks that catch meaning drift, tiering you can defend in writing, and terminology control across thousands of dossier pages.
By Julio G. Martinez-Clark